Lanoxicaps

   
Google
 
Web NewDrugInformation.com

Lanoxicaps


Drug - Lanoxicaps
The trade name of the product as shown on the labeling.

Dosage - CAPSULE; ORAL
The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Digoxin
Multiple ingredients are in alphabetical order.

Strength - 0.05MG
The potency of the active ingredient(s), Digoxin. May repeat for multiple part products.

Applicant - SMITHKLINE BEECHAM
The firm name holding legal responsibility for Lanoxicaps. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 018118
The FDA assigned number to Lanoxicaps. Format is nnnnnn.

Product Number - 002
The FDA assigned number to identify Lanoxicaps. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code -
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - Jul 26, 1982
The date Lanoxicaps was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - No
The pioneer or innovator of Lanoxicaps. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - RX
The group or category of approved drugs Lanoxicaps is in. Format is RX, OTC, DISCN.

Applicant Full Name - Smithkline Beecham Corp Dba Glaxosmithkline
The full name of the firm holding legal responsibility for the new application of Lanoxicaps.

Lanoxicaps